Santhosh K. Pasupuleti, PhD
Assistant Research Professor of Pediatrics
- skpasupu@iu.edu
- Phone
- (317) 274-0303
- Address
-
R4 169
PNEB
IN
Indianapolis, IN - PubMed:
-
Bio
Dr. Santhosh Kumar Pasupuleti earned his PhD in Biotechnology from Sri Venkateswara Institute of Medical Sciences University, India, specializing in human hematopoietic stem cells (HSCs). His doctoral research focused on the differentiation of erythrocytes, platelets, and hepatocytes from human HSCs, with a particular emphasis on drug-resistant BCR-ABL mutant patients suffering from chronic myeloid leukemia, as well as polycythemia vera and congenital erythrocytosis.
Following his PhD, Dr. Pasupuleti pursued a postdoctoral fellowship at the Department of Pediatrics, Indiana University School of Medicine, Indianapolis. There, he investigated the role of mutations associated with pre-leukemic or clonal hematopoiesis of indeterminate potential (CHIP), including Dnmt3a, Asxl1, Tet2, and Jak2, in the development of clonal hematopoiesis (CH) and various forms of leukemia such as acute myeloid leukemia (AML) and severe myeloproliferative neoplasms (MPN), particularly in the context of obesity and/or diabetes. His research also extensively covered juvenile myelomonocytic leukemia (JMML), a pediatric blood cancer.
Dr. Pasupuleti currently serves as Assistant Research Professor within the Program in Hematologic Malignancies and Stem Cell Biology at the Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis.
Key Publications
https://pubmed.ncbi.nlm.nih.gov/?term=Pasupuleti+Santhosh+Kumar
https://scholar.google.com/citations?user=smaUIvlEKycC&hl=en
| Year | Degree | Institution |
|---|---|---|
| 2019 | PhD | Sri Venkateswara Institute of Medical Sciences |
| 2010 | M.Sc. | Bharathiar University |
| 2008 | BSC | Sri Venkateswara University |
Dr. Pasupuleti's research interests, include elucidating the role of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations such as TET2, DNMT3a, ASXL1, and JAK2 in blood cell lineages involving the expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy and cardiovascular disease (CVD). Dr. Pasupuleti’s recent findings that obesity and/or diabetes-induced inflammation promote CHIP driven exacerbated clonal hematopoiesis (CH), leading to severe MPN/AML as well as CVD, via aberrant activation of intracellular calcium (Ca2+) levels and pro-inflammatory cytokines. Dr. Pasupuleti is also, interested in mechanisms of how gain-of-function Shp2E76K/+ mutation drive hematopoietic dysregulation and Juvenile myelomonocytic leukemia (JMML) development. Recently, we show that a combination of MEK inhibitor and hypomethylating agent, 5-azacitidine rescue Shp2-driven JMML. Dr. Pasupuleti was also, involved in Phase I/II trial of augmenting TAK-659 action in relapse/refractory AML by addition of proteasome inhibitor Ixazomib: BTCRC-HEM17-092.
Desc: Leukemia Research New Investigator Research Grant
Scope: International
Date: 2024-07-01
Desc: Ralph W. and Grace M. Showalter research grant award
Scope: International
Date: 2024-06-01
Desc: Herman B Wells Center for Pediatric Research Seed Funding Grant
Scope: International
Date: 2024-02-01
Desc: Hematopoiesis and Hematologic Malignancies (HHM) Basic Science grant award
Scope: International
Date: 2023-08-01
Desc: Clinical/Translational research grant award
Scope: International
Date: 2023-08-01
Desc: Abstract achievement award
Scope: National
Date: 2021-12-12
Desc: Endowment Award (Gold medal) for Best Case Report
Scope: National
Date: 2019-02-26
Desc: Certificate of Appreciation in Teaching
Scope: National
Date: 2018-01-26
Desc: Grant for PhD thesis
Scope: National
Date: 2017-08-06
Desc: Best First oral paper presentation award
Scope: National
Date: 2017-02-06
Desc: Young Scientist Award
Scope: National
Date: 2016-11-12